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Abstract 
Background: To determine the impact of the introduction of artemisinin-based combination therapy (ACT) on 
parasite susceptibility, a molecular surveillance for antimalarial drug resistance was conducted on local isolates from 
the Hôpital Principal de Dakar between November 2013 and January 2014 and between August 2014 and December 
2014.
Methods: The prevalence of genetic polymorphisms in antimalarial resistance genes (pfcrt, pfmdr1, pfdhfr and 
pfdhps) was evaluated in 103 isolates.
Results: The chloroquine-resistant haplotypes CVIET and CVMET were identified in 31.4 and 3.9 % of the isolates, 
respectively. The frequency of the pfcrt K76T mutation was increased from 29.3 % in 2013–2014 to 43.2 % in 2014. 
The pfmdr1 N86Y and Y184F mutations were identified in 6.1 and 53.5 % of the isolates, respectively. The pfdhfr triple 
mutant (S108N, N51I and C59R) was detected in the majority of the isolates (82.3 %). The prevalence of quadruple 
mutants (pfdhfr S108N, N51I, C59R and pfdhps A437G) was 40.4 %. One isolate (1.1 %) harboured the pfdhps mutations 
A437G and K540E and the pfdhfr mutations S108N, N51I and C59R.
Conclusions: Despite a decline in the prevalence of chloroquine resistance due to the official withdrawal of the drug 
and to the introduction of ACT, the spread of resistance to chloroquine has continued. Furthermore, susceptibility to 
amodiaquine may be decreased as a result of cross-resistance. The frequency of the pfmdr1 mutation N86Y declined 
while the Y184F mutation increased in prevalence, suggesting that selective pressure is acting on pfmdr1, leading to a 
high prevalence of mutations in these isolates and the lack of specific mutations. The 50.5 % prevalence of the pfmdr1 
polymorphisms N86Y and Y184F suggests a decrease in lumefantrine susceptibility. Based on these results, intensive 
surveillance of ACT partner drugs must be conducted regularly in Senegal.
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Background
Due to increasing chloroquine resistance, the first-line 
malaria treatment in Senegal was switched to sulfadox-
ine–pyrimethamine with amodiaquine in 2004. In 2006, 
the Senegalese National Malaria Control Programme 
recommended artemisinin-based combination therapy 
(ACT) as the first-line treatment for uncomplicated 
malaria. Therefore, the first-line therapy for uncom-
plicated malaria became artemether–lumefantrine or 
artesunate–amodiaquine. The dihydroartemisinin–
piperaquine combination was then recommended as a 
second-line treatment for uncomplicated Plasmodium 
falciparum malaria in Senegal.
Intermittent preventive treatment (IPT) consists of 
administering sulfadoxine–pyrimethamine and one dose 
of artesunate during the transmission season and resulted 
in a 90  % reduction in incidence of clinical malaria in 
Senegal [1]. Administered once a month to all children 
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or pregnant women, this seasonal IPT can provide a high 
degree of protection against malaria.
The combination of sulfadoxine–pyrimethamine and 
amodiaquine was more effective than sulfadoxine–
pyrimethamine and artesunate or amodiaquine and artesu-
nate in malaria preventive treatment [2]. During IPT with 
sulfadoxine–pyrimethamine and piperaquine, only 3.4 % of 
the treated children had malaria [3].
Since the introduction of ACT and IPT trials in Sen-
egal, very few studies have examined P. falciparum resist-
ance to antimalarial drugs. To determine the impact of 
the introduction of new anti-malarial drugs on parasite 
susceptibility, a molecular study of anti-malarial drug 
resistance was conducted on local isolates from the 
Hôpital Principal de Dakar between November 2013 and 
January 2014 and between August 2014 and December 
2014. The prevalence of genetic polymorphisms in anti-
malarial resistance genes, such as the P. falciparum chlo-
roquine resistance transporter (pfcrt) for chloroquine [4], 
P. falciparum multidrug resistance 1 (pfmdr1), which is 
involved in mefloquine resistance [5] and potentially in 
quinoline resistance [6, 7], P. falciparum dihydrofolate 
reductase (pfdhfr) for pyrimethamine [8] and P. falcipa-




In total, 103 symptomatic patients were recruited at the 
Hôpital Principal de Dakar. Fifty-nine P. falciparum iso-
lates were collected between November 2013 and Janu-
ary 2014 and 44 between August 2014 and December 
2014. The majority of patients (64  %) were recruited 
from the emergency department. The other patients were 
recruited from the intensive care unit (12 %), paediatric 
department (7 %), infectious diseases department (5 %), 
maternity department (3 %), and other units (9 %). Anti-
malarial treatment prior to admission was not recorded. 
Despite the WHO’s recommendations, the P. falciparum 
treatment administered at the Hôpital Principal de Dakar 
until November 2014 was quinine followed by artesunate 
or artemether–lumefantrine. All the patients or their 
parents/guardians provided their verbal consent before 
blood collection. The ethical committee of the Hôpital 
Principal de Dakar approved the study.
Peripheral venous blood samples were collected in 
Vacutainer® ACD tubes (Becton–Dickinson, Rutherford, 
NJ, USA) prior to patient treatment. The diagnosis was 
performed on thin blood smears stained using a RAL® kit 
(Réactifs RAL, Paris, France) to determine P. falciparum 
density and to confirm species-specific monoinfection. 
The level of parasitaemia ranged from 0.001 to 3.3 % in 
2013–2014 and 0.06 to 14.1 % in 2014.
Nucleic acid extraction
Total genomic DNA was extracted from blood sample 
using a QIAamp DNA Blood Mini Kit according to the 
manufacturer’s recommendations (Qiagen, Germany).
Anti‑malarial resistance gene single‑nucleotide 
polymorphisms (SNPs)
Four genes, pfcrt, pfmdr1, pfdhfr and pfdhps, were ampli-
fied by PCR using the reaction conditions described in 
Table 1 [10–12]. The reaction mixture included 2.5 µL of 
genomic DNA, 1X reaction buffer (Eurogentec), 200 µM 
of deoxynucleoside triphosphate mixture (dGTP, dATP, 
dTTP and dCTP) (Euromedex, Souffelweyersheim, 
France), variable concentration of MgCl2 (Table  1), 
0.32 µM of forward and reverse primers and one unit of 
Red Diamond Taq® DNA polymerase (Eurogentec) in a 
final volume of 25 µL. The thermal cycler (T3 Biometra, 
Archamps, France) was programmed as follows: an ini-
tial denaturation at 94 °C for 5 min followed by 40 cycles 
of 94  °C for 30  s, specific hybridization temperature for 
variable elongation times (Table 1) and 72  °C for exten-
sion at 1  min per 1000  bp, and a final 5  min extension 
step at 72 °C. Purified genomic DNA from P. falciparum 
clone 3D7 was used as a positive control, and water and 
human DNA were used as negative controls. The reaction 
products were sequenced using the BigDye Terminator 
v3.1 Cycle Sequencing Kit (Applied Biosystems) with the 
primers described in Table  1. The sequencing reaction 
products were purified using the BigDye XTerminator® 
Purification Kit (Applied Biosystems) in accordance with 
the manufacturer’s instructions. Sanger sequencing of 
PCR products was performed using an ABI Prism 3100 
analyser (Applied Biosystems). The sequence data were 
analysed using Vector NTI Advance™ software (version 
11, Invitrogen, Cergy Pontoise, France).
Results
Of 103 P. falciparum isolates collected at the Hôpital 
Principal de Dakar, 59 isolates were obtained between 
November 2013 and January 2014 and 44 between 
August 2014 and December 2014.
The pfcrt gene was successfully sequenced in 102 sam-
ples. The frequency of the haplotype CVIET was 31.4 % 
(n = 32 isolates), the haplotype CVMET was 3.9 % (n = 4 
isolates) and the haplotype CVMNK was 64.7 % (n = 66 
isolates). A molecular resistance profile was identified in 
35.3 % of cases (n = 36 isolates), including 29.3 % (n = 17 
isolates) in 2013–2014 and 43.2  % (n  =  19 isolates) in 
2014. The difference is not significant (P value =  0.146, 
Pearson’s Chi squared test). The CVEMT haplotype was 
first identified in the 2014 malaria season.
The results for pfmdr1 polymorphisms are shown in 
Table  2. The frequency of the 86Y mutation was 5.1  % 
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(n = 5 isolates), and one mixed sample (1 %) harboured 
both N86 and 86Y alleles. The 184F mutation frequency 
was 53.5 % (n = 53 isolates), and five of the six isolates 
harboured both the 86Y and 184F codons. Parasites with 
the N86 allele and the 184F mutation represented 50.5 % 
of the isolates. No new SNPs were detected in the pfmdr1 
gene.
The results for pfdhfr polymorphisms are presented in 
Table  3. The mutation frequencies were 87.9  % for the 
S108N mutation and 85.9 % for both the N51I and C59R 
polymorphisms. The triple mutant (S108N, N51I and 
C59R) was detected in 82.3 % of samples.
The results for the pfdhps polymorphisms are presented 
in Table 4. The isolates harboured A437G in 47.2 % of the 
cases, S436A in 20.2 % of the cases, A613S in 3.2 % of the 
cases, K540E in 2.1 % of the cases and A581G in 1.1 % of 
the cases.
The prevalence of the quadruple mutant (pfdhfr 108N, 
51I, 59R and pfdhps 437G) was 40.4 %. One isolate (1.1 %) 
simultaneously harboured the two pfdhps mutations 
437G and 540E and the three pfdhfr mutations 108N, 51I 
and 59R.
Discussion
In total, isolates from only 103 malaria patients were col-
lected in 2013 and 2014 at the Hôpital Principal de Dakar, 
55 during the 2013–2014 malaria season and 44 dur-
ing the 2014–2015 season. This is due to the decreased 
prevalence of malaria in Senegal (reduction of 27.6  % 
from 2013 to 2014) [13]. Chloroquine resistance is prin-
cipally mediated by pfcrt mutations in different parts of 
the world [14]. In this study, the pfcrt gene was mutated 
in 35.3 % of the patients recruited at the Hôpital Princi-
pal de Dakar in 2013 and 2014, including 29.3  % of the 
Table 1 PCR for anti-malarial resistance genes
Gene Primers Amplicon (pb) [MgCl2] (mM) Tm (°C) Elongation time (s)
pfcrt Forward CRT76-F 182 4.5 55 20
TTG GTA AAT GTG CTC ATG TG T
Reverse CRT76-R
ACA AAT AAA GTT GTG AGT TTC GGA TG
pfmdr1-1 Forward MDR1-1F 610 2.5 52 30
AGA GAA AAA AGA TGG TAA CCT CAG
Reverse MDR1-1R
ACC ACA AAC ATA AAT TAA CGG
pfmdr1-2 Forward MDR1-2F 890 2.5 56 60
CAG GAA GCA TTT TAT AAT ATG CAT
Reverse MDR1-2R
CGT TTA ACA TCT TCC AAT GTT GCA
pfdhfr Forward Dhfr-F 562 2.5 52 20
ACG TTT TCG ATA TTT ATG C
Reverse Dhfr-R
TCA CAT TCA TAT GTA CTA TTT ATT C
pfdhps Forward Dhps-F 971 2.5 53 20
TTT TGT TGA ACC TAA ACG TG
Reverse Dhps-R
AAA CGT CAT GAA CTC TTA TTA GAT
Table 2 Frequency (%) and  number (no) of  the pfmdr1 
mutations
Codon No Wild type % 
(no)
Mutated % (no) Wild type/
mutated % (no)
N86Y 99 93.9 (93) 5.1 (5) 1 (1.0)
Y184F 99 46.5 (46) 53.5 (53) 0 (0)
S1034C 102 100 (102) 0 (0) 0 (0)
N1042D 102 100 (102) 0 (0) 0 (0)
Table 3 Frequency (%) and  number (no) of  the pfdhfr 
mutations
Codon No Wild type % (no) Mutated % (no)
S108N 99 12.1 (12) 87.9 (87)
N51I 99 14.1 (14) 85.9 (85)
C59R 99 14.1 (14) 85.9 (85)
I164L 99 100 (99) 0 (0)
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cases in the 2013–2014 season and 43.2  % of the cases 
in the 2014–2015 season. This increase in chloroquine 
resistance has been observed in recent years following a 
decrease due to the withdrawal of chloroquine and the 
introduction of ACT in 2002 in Senegal (Table 5). Before 
the introduction of ACT in Senegal, the prevalence of 
isolates harbouring the pfcrt K76T and in  vitro chloro-
quine resistance was above 50 and 40 %, respectively, in 
Dakar and its suburb Pikine and in south areas (Dielmo 
and Ndiop) [15–21]. During the beginning of the ACT 
implementation (2004–2009), the prevalence of K76T 
mutant parasites maintained around 50 % [19, 22]. From 
2009 to 2011, the prevalence of K76T mutant parasites 
and in vitro chloroquine resistance decreased to 40 and 
25 %, respectively in Dakar [23–25]. Since 2013, the level 
of chloroquine resistance has increased again to that of 
2002 in Dakar [26, 27].
While chloroquine is no longer used in Senegal, the 
prevalence of in  vitro chloroquine resistance and of the 
pfcrt K76T mutation has increased. Two hypotheses 
could explain the observed increase: (i) the use of artesu-
nate–amodiaquine in Senegal led to the emergence of 
resistant parasites to amodiaquine; (ii) the development 
of cross-resistance to chloroquine and monodesethyla-
modiaquine increased the resistance [23, 28]. This study 
describes the first detection of the CVMET haplotype 
in Senegal. In Senegal, the 76T mutation has previously 
been associated with the CVIET haplotype.
The isolates harbouring the pfmdr1 mutations 86Y, 
184F, 1034C and 1042D were identified in 6.1, 53.5, 0 and 
0  % of the patients, respectively. The prevalence of 86Y 
has decreased over the past few years in Senegal from 
>30 % in 2000 to 6 % in 2013–2014 (Table 6) [18–20, 22, 
24, 25]. Since 2010, the prevalence of parasites harbour-
ing the 184F mutation has remained stable and above 
50  % in Dakar [24, 25]. This prevalence has more than 
doubled from 30 % in 2008 to greater than 70 % in 2011 
in Thiès [22]. The frequency of the pfmdr1 mutation 
N86Y declined, while the frequency of the Y184F muta-
tion increased, suggesting that selective pressure is acting 
on pfmdr1, leading to a high prevalence in these isolates 
and the lack of specific mutations. The role of polymor-
phisms in pfmdr1 is still debated. The 86Y mutation was 
associated with increased in vitro susceptibility of P. fal-
ciparum parasites to dihydroartemisinin, lumefantrine, 
monodesethylamodiaquine and mefloquine [29]. In con-
trast, this pfmdr1 86Y mutation was associated with a 
decrease of in vitro susceptibility to dihydroartemisinin, 
lumefantrine, and mefloquine in P. falciparum isolates 
from Asia [30], Kenya [31] and Benin [32]. Field studies 
in east Africa have also shown selection of the N86 allele 
Table 4 Frequency (%) and  number (no) of  the pfdhps 
mutations
Codon No Wild type % (no) Mutated % (no)
S436A 89 79.8 (71) 20.2 (18)
A437G 89 52.8 (47) 47.2 (42)
K540E 94 14.1 (97.9) 2.1 (2)
A581G 94 98.9 (93) 1.1 (1)
A613S 94 96.8 (91) 3.2 (3)
Table 5 Molecular (pfcrt K76T) and in vitro studies on evaluation of P. falciparum susceptibility to chloroquine in Senegal
Year of collection Site of collection In vitro chloroquine resistance (%) pfcrt 76T References
1996 Dielmo/Ndiop 49 [15]
1997–1998 Dielmo/Ndiop 43.5 [16]
1999 Dielmo/Ndiop 55 [17]
2000 Pikine 31 79 % [18]
2000–2003 Pikine 72.4 % [19]
2001 Pikine 64 % [20]
2002 Dakar 52 54 % [21]
2004–2005 Pikine 47.2 % [19]
2006–2009 Pikine 59.5 % [19]
2008–2011 Thies >50 % [22]
2009–2010 Dakar 22 [23]
2009–2010 Dakar 37.2 [24]
2010–2011 Dakar 24.2 43.6 % [25]
2013–2014 Dakar 50 [26]
2013–2014 Dakar 29.3 Present data
2014 Dakar 52.8 [27]
2014 Dakar 43.2 % Present data
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in recurrent infections after treatment with artemether 
plus lumefantrine [33–36] or artesunate plus meflo-
quine [37], which suggests that N86 is a marker of in vivo 
lumefantrine resistance. In addition, parasites harbour-
ing both the N86 and 184F alleles were less susceptible 
to lumefantrine and mefloquine in vitro [29]. This profile 
was detected in 50.5 % of the isolates collected in Dakar.
Conversely, the pfmdr1 86Y mutation has been shown 
to be associated with in vivo amodiaquine resistance dur-
ing recrudescence after amodiaquine monotherapy [38] 
or after combination therapy with artesunate–amodi-
aquine [39]. The odds ratio for amodiaquine therapeutic 
failure associated with the 86Y mutation was 5.4 [40]. 
These results may suggest a low prevalence of P. falcipa-
rum strains resistant to amodiaquine in Dakar. These data 
are in contrast with previous studies in Senegal: (i) the 
86Y mutation was significantly associated with increased 
susceptibility to monodesethylamodiaquine, the active 
metabolite of amodiaquine, in parasites collected from 
2009 to 2011 in Dakar [29]; (ii) the prevalence of isolates 
with reduced in  vitro susceptibility to monodesethyla-
modiaquine increased significantly from 5.6 % in 2013 to 
30.6  % in 2014 with an increase in IC50 values from 9.8 
to 25.3 nM [26, 27]; (iii) the re-increase of P. falciparum 
strains resistant to chloroquine appears to be due to cross-
resistance between in  vitro susceptibility to chloroquine 
and monodesethylamodiaquine [23, 28] and the use of 
artesunate–amodiaquine in Senegal, which can generate 
the emergence of parasites resistant to amodiaquine. The 
increase in amodiaquine IC50 values was already observed 
in isolates collected in Thiès between 2008 and 2011 [22].
The pfdhfr 108N mutation has been found to be cor-
related with in vitro and in vivo resistance to pyrimeth-
amine [5, 41]. The risk of therapeutic failure with 
sulfadoxine–pyrimethamine was greater for patients har-
bouring the 108N mutation (odds ratio of 3.5) during a 
28  day follow-up [40]. Additional mutations—51I (odds 
ratio of 1.7) or 59R (odds ratio of 1.9)—increase the level 
of in  vitro resistance to anti-folate drugs and sulfadox-
ine–pyrimethamine [40]. The risk of in  vivo resistance 
to sulfadoxine–pyrimethamine increased by 4.3 with the 
triple mutation (108N, 51I and 59R) [40]. In 2013–2014, 
the prevalence of the pfdhfr 108N mutation was 87.9 % in 
malaria patients who were treated at the Hôpital Princi-
pal de Dakar. dhfr triple mutants at codons 51I, 59R and 
108N were associated with high-level pyrimethamine 
resistance and represented 82.3  % of the isolates. Since 
2002, the prevalence of triple mutants has increased from 
50 to 82.3  % in 2013–2014 (Table  7). This increase was 
observed in different areas of Senegal [3, 42, 43].
The pfdhps 437G mutation has been shown to be corre-
lated with in vitro and in vivo resistance to sulfadoxine [6]. 
The risk of therapeutic failure with sulfadoxine–pyrimeth-
amine increased by 1.5 and 3.9 with the single muta-
tion A437G and the double mutation A437G and K540E, 
respectively [40]. In 2013–2014, 47.2  % of the isolates 
harboured the 437G mutation in Dakar. This prevalence 
increased after 2002 and was then stable from 2009 to 2014 
with 40–50 % of the isolates harbouring the 437G mutation 
in Senegal (Table 8). Several studies from 2006 to 2008 in 
Senegal showed that the prevalence of pfdhps 437G sig-
nificantly increased after IPT of infants with sulfadoxine–
pyrimethamine [3, 44]. Only two isolates (2.1 %) carried the 
double mutation (437G and 540E) that is associated with 
high-level sulfadoxine resistance. The pfdhps mutation of 
codon 613 (A613S) (3.2 %) is very rare in Africa.
In Dakar, the prevalence of isolates harbouring the 
quadruple mutants (dhfr 108N, 51I, 59R and dhps 437G) 
was stable from 2009 to 2014: 36.5 % in 2009, 36.7 % in 
2010 and 40.4 % in 2014 [24, 25]. In Thiès, the prevalence 
of quadruple mutants increased from 20 to 66 % between 
2003 and 2011 and then dropped to 44  % in 2013 [43]. 
In 2010, the quadruple mutants were identified in 79.4 % 
of the isolates from areas of Senegal where sulfadoxine–
pyrimethamine plus amodiaquine were administered 
Table 6 Evolution of  pfmdr1 N86Y mutation in  P. falcipa-
rum parasites in Senegal
Year of collection Site of collection N86Y References
2000 Pikine 31 % [18]
2001 Pikine 30.6 % [20]
2002–2003 Pikine 40 % (about) [19]
2005–2009 Pikine 20 % (about) [19]
2009 Thiès 20 % (about) [22]
2009–2010 Dakar 17.2 % [24]
2010–2011 Dakar 16.1 [25]
2011 Thiès <5 % [22]
2013–2014 Dakar 6.1 % Present data
Table 7 Evolution of pfdhfr 51I, 59R and 108N triple muta-





51I, 59R, 108N 
(%)
References
2002 Dakar 50 [21]
2003 Pikine 61 [42]
2003 Thies 40 [43]
2007 Keur Soce 67 [3]
2009–2010 Dakar 75.3 [24]
2010–2011 Dakar 73.6 [25]
2011 Thiès 93 [43]
2013–2014 Dakar 82.3 Present data
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to children during seasonal malaria chemoprevention 
versus 67.1 % in areas where they were not treated [45]. 
In 2014, only one isolate harboured the pfdhps muta-
tions 437G and 540E and the pfdhfr mutations 108N, 51I 
and 59R; these mutations are associated with high-level 
sulfadoxine–pyrimethamine resistance. These findings 
suggest that regular surveillance of molecular markers 
should be performed in areas where IPT with sulfadox-
ine–pyrimethamine is used.
In summary, the prevalence of chloroquine resistance 
continues to increase after a decline due to the official 
withdrawal of the drug and the introduction of ACT. Fur-
thermore, amodiaquine susceptibility may be decreased 
as a result of cross-resistance. The frequency of the 
pfmdr1 mutation N86Y declined while the frequency of 
the Y184F mutation increased, suggesting that selective 
pressure is acting on pfmdr1, leading to a high prevalence 
in these isolates and the lack of specific mutations. The 
50.5  % prevalence of the pfmdr1 polymorphisms N86 
and 184F suggests a decrease in lumefantrine susceptibil-
ity. Based on these results, intensive surveillance of ACT 
partner drugs must be conducted regularly in Senegal.
Furthermore, molecular surveillance in Dakar has dem-
onstrated the emergence of polymorphisms in the K13 
propeller domain gene, which is associated with in vitro 
and in  vivo resistance to artemisinin in Asia [46–48]. 
However, these mutations detected in Dakar and more 
generally in Africa have not yet been associated with 
artemisinin resistance.
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